Skip to main content
. 2022 Aug 5;28(21):4724–4736. doi: 10.1158/1078-0432.CCR-22-0301

Figure 3.

Figure 3. Efficacy of AZD5305 in BRCAm xenograft tumor models. Antitumor efficacy of AZD5305 dose-responses in MDA-MB-436 BRCA1 m TNBC xenograft (A), in CAPAN-1 BRCA2 m pancreatic cancer xenograft (B), and in isogenic xenograft tumor models DLD-1 BRCA2−/− (C) and DLD-1 WT (D). Mice were dosed with indicated doses of AZD5305 or 100 mg/kg olaparib once daily orally (PO) for 35 (A, B), 31 (C) or 20 (D) days. E and F, In experiments from A and C treatment was withdrawn as indicated and tumors were monitored for the regrowth. Graphs depict geomean tumor volume ±SEM and percent tumor growth inhibition (TGI) or regression (reg). Statistical significance was evaluated compared with the vehicle group using a one-tailed t test (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001).

Efficacy of AZD5305 in BRCAm xenograft tumor models. Antitumor efficacy of AZD5305 dose–responses in MDA-MB-436 BRCA1m TNBC xenograft (A), in Capan-1 BRCA2m pancreatic cancer xenograft (B), and in isogenic xenograft tumor models DLD-1 BRCA2−/− (C) and DLD-1 WT (D). Mice were dosed with indicated doses of AZD5305 or 100 mg/kg olaparib once daily orally for 35 (A, B), 31 (C), or 20 (D) days. E and F, In experiments from A and C, treatment was withdrawn as indicated and tumors were monitored for the regrowth. Graphs depict geomean tumor volume ±SEM and percent tumor growth inhibition (TGI) or regression (reg). Statistical significance was evaluated compared with the vehicle group using a one-tailed t test (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001).